Skip to main content

Table 1 Summary of indicators used to create the composite score of continuous care uptake for people living with HIV on antiretroviral therapy

From: Measuring the uptake of continuous care among people living with HIV receiving antiretroviral therapy and social determinants of the uptake of continuous care in the southwest of China: a cross-sectional study

Indicator Source Definition Goal
Clinic visit NFATP Frequency of patient's visits at an HIV clinic in the past six months for ART drug refill Two or more in the past six months
Routine test NFATP Frequency of respondent's free routine testing including simple renal function (i.e., plasma creatinine, urea), liver function (i.e., alanine aminotransferase and aspartate aminotransferase), complete blood cell counts in the last 12 months for monitoring toxicity of ART Four or more in the past 12 months
CD4 count NFATP and outpatient system Frequency of respondent's CD4 testing in the last 12 months for immunological monitoring For counts between 300 and 500 cells/mm3, receiving at least one test in the last 12 months, and for counts less than 300 cells/mm3, receiving at least two tests in the last 12 months [12, 34]
Viral load assay NFATP and outpatient system Frequency of respondent's viral load assay in the last 12 months for virological monitoring At least twice in the last 12 months [12, 34]
Mental health assessment Self-report Respondent's answer to the question "Have you received a mental health assessment from a health provider in the last 12 months?" with "Yes" or "No" Received in the last 12 months
Mental health counseling Self-report Respondent's answer to the question "Have you received mental health counseling from a health provider in the last 12 months?" with "Yes" or "No" Received in the last 12 months
BMD Outpatient system Whether the respondent had a lumbar spine and femur BMD by dual-energy X-ray absorptiometry scanner in the last 12 months Received in the last 12 months
Evaluation of CKD risk Outpatient system Whether the respondent received evaluation of the risk of CKD, including calculation of creatinine clearance (Cockcroft-Gault' formula), urinalysis with urine glucose, urine protein and urinary β 2-microglobulin in the last 12 months Received in the last 12 months
Monitoring CVD risk Outpatient system Whether the respondent received measurement of blood lipids and blood pressure for monitoring risk of CVD in the last 12 months Received in the last 12 months
ECG Outpatient system Whether the respondent had an ECG in the last 12 months Received in the last 12 months
TB screening Outpatient system Whether the respondent had a chest X-ray and further sputum smear in the last 12 months Received in the last 12 months
Hepatitis B serologic testing Outpatient system Whether the respondent had testing of HBV antigen and antibody, or HBV-DNA in the last 12 months Received in the last 12 months
Hepatitis C serologic testing Outpatient system Whether the respondent had testing for anti-HCV, HCV-RNA, or other HCV genotype in the last 12 months Received in the last 12 months
Syphilis serological testing Outpatient system Whether the respondent had testing a nontreponemal test (i.e., RPR) and a treponemal test (i.e., the TP-PA) in the last 12 months Received in the last 12 months
  1. BMD bone mineral density, CKD chronic kidney diseases, CVD cardiovascular diseases, ECG electrocardiogram, TB tuberculosis, HBV/HCV hepatitis B/C virus, NFATP National Free Antiretroviral treatment program, RNA Ribonucleic acid, DNA Desoxyribonucleic acid, RPR rapid plasma regain, TP-PA T. pallidum passive particle agglutination assay